4 Stocks I’d Sell NOW — Even If Tom Lee Is Right

4 Stocks I’d Sell NOW — Even If Tom Lee Is Right

Analyzed Watch on YouTube Requested On
Video return
+1.16%
Calls
3
Buy / Sell
0 3
Published

Recommendations

Entry is the asset's closing price on the publication date. Current is the last close on record.

  1. 01 AAPL NASDAQ SELL +1.71%
    Entry $348.51 10 Nov 2026
    Current $342.56 20 Nov 2026
    Result +$5.95
    vs. index +9.7% SPY −8.0% over the same days
    Surrounding source transcript
    …a premium of 29% and if we work backwards from the market price today of $350 while the stock it needs roughly 13.3% annual cash flow growth for a decade that's the hurdle I'm weighing against a starting point that's already a record year. My call for Apple near $350 is to take some money off the table. If the earnings trajectory gets stronger, I can revisit what I pay at this price. For me, I'd reduce the Apple position. So, Apple for me is going in the trim column with roughly 270 to 280 as the range I'd revisit for this. The next stock though is got a much bigger one-day bounce and the model gives me a different answer. And before we jump into that stock…

    My call for Apple near $350 is to take some money off the table. If the earnings trajectory gets stronger, I can revisit what I pay at this price. For me, I'd reduce the Apple position.

    AI-extracted context My call for Apple near $350 is to take some money off the table. If the earnings trajectory gets stronger, I can revisit what I pay at this price. For me, I'd reduce the Apple position. So, Apple for me is going in the trim column with roughly 270 to 280 as the range I'd revisit for this.

  2. 02 JNJ NYSE SELL +3.67%
    Entry $280.78 10 Nov 2026
    Current $270.47 20 Nov 2026
    Result +$10.31
    vs. index +11.7% SPY −8.0% over the same days
    Surrounding source transcript
    …e will pay. If the multiple falls back towards the historical range, it can eat into the growth. Johnson and Johnson. It has the largest premium of my four trims using these models, which makes it the first one I'd review in the portfolio. So for me today, J&J is a trim at this level. Around $200 is where I'd revisit the thesis based on the work. At $282, I take advantage of what investors are willing to pay for the shares. So that's two trim so far. The next stock has also had a big run, and the later results make the …

    So for me today, J&J is a trim at this level.

    AI-extracted context Johnson and Johnson. It has the largest premium of my four trims using these models, which makes it the first one I'd review in the portfolio. So for me today, J&J is a trim at this level. Around $200 is where I'd revisit the thesis based on the work. At $282, I take advantage of what investors are willing to pay for the shares.

  3. 03 WMT NASDAQ SELL -1.91%
    Entry $125.55 10 Nov 2026
    Current $127.95 20 Nov 2026
    Result −$2.40
    vs. index +6.1% SPY −8.0% over the same days
    Surrounding source transcript
    … the DCF we get to $101 indicating a 24% premium today. I can see why warm up would get a higher multiple than it used to. How much higher is the question. With a yield below 1%, you're leaning on growth and the multiple staying high. Now, Walmart reports on November 19th around 125, I'd probably take some money off the table. What could change my mind is clearer evidence that today's spending is turning into durable cash flow. I'd put Walmart in the trim column. Around $100 is where I'd revisit on these assumptions. The dividend model, it gives you a reason for a different view. The cash flow hurdle, it settles it for me. At the next report, check this figure alongside cash flow. If both are impro…

    Walmart reports on November 19th around 125, I'd probably take some money off the table. What could change my mind is clearer evidence that today's spending is turning into durable cash flow. I'd put Walmart in the trim column.

    AI-extracted context Walmart reports on November 19th around 125, I'd probably take some money off the table. What could change my mind is clearer evidence that today's spending is turning into durable cash flow. I'd put Walmart in the trim column. Around $100 is where I'd revisit on these assumptions.

Full Transcript
Tom Lee thinks last week was the bottom. And I've ran the numbers on six stocks, and I'd still take money off the table on four cases. Now, look at the map. This is the S&P in the last month. We've got some familiar names. They've barely even felt the sell-off. And then when we transition to over one week, while Amazon, that's up nearly 7%. We've got Nvidia, that's down more than 13. There's a big difference between being right about the index and being right about the stock that you own. And if we look at the market overall, well, the S&P 500 that's trading 17.7 times forward earnings. The long run average that's around 16.4. So yes, prices have come down, but you still have to decide what as an investor you're prepared to pay. And then look at Staples. In fact, they're well above their own historical multiple. They're trading 23.7. The 25 year average, that's sitting just below 18. I'm going to show you today four positions I'd reduce and two that I'd keep. But first, we're going to listen to the specific signal that made Tom Lee so bullish. >> You gosh, you did not expect the huge draw down that we had last week and here we are with this huge run today. What's it mean to you in the big picture? >> Um, I think there were two encouraging data points today. Um, the first is we had a a flurry of bad news over the weekend. one involving Nvidia and and some about Texas going after Elon Musk companies and yet the markets are at those stocks are rallying today. I think that's a good sign that markets are rallying on bad news. But the second is the VIX uh the VIX term structure which is the 4month VIX versus the one-mon that inverted last week. It's now normalized today. That's usually a sign of a bottom. So I I think that this is more proof that last week was the low. The part I'm taking from that is how the market absorbed the bad news. It tells me there can be buyers on the other side of a sell order even while there's plenty of uncertainty. Now look at the spread in the draw downs of stocks from their highs. Apple, well that's sitting close to its high, only 1% off while we've got other big names. They're miles off. It makes Apple today my first test. What are you paying when you buy that strength? Now it closed yesterday around $350. is up year to date 29% over the last 5 years more than a double up 133 in fact trading around their all-time highs as we said only around 1% off where we only get one buy rating and it's very weak from Wall Street 3.8 out of five. So why exactly would I trim Apple here? Well firstly let's look at their latest quarter. The middle of this chart here is pointing out that Apple did $115 billion of revenue for the quarter that was up 12% year-over-year. That's a very strong quarter, especially for a company the size of Apple. And you can also see the improvement it's building over several quarters. The blue bars, they're the trailing earnings per share. Orange line here is the trailing revenue growth. Both have moved up and that's a big part of the bullcase for the company. I mean, we've got iPhone. They did nearly 58 billion of revenue. That's up 17% year-over-year. Services, well, that was $ 32 billion, up 10%. When both lines are growing like this, it's very easy to see why investors want to own Apple. And something we can't say for many big tech, the money actually came through operating cash flow minus capex. It came to $136 billion for the year. That's up from around 99 billion. That's the highest figure that Apple has ever produced. And we've also got a balance sheet argument for the premium as well. We've got trailing net debt that's sitting at 0.2 times EBITRA. I'm comfortable with the business having the financial room to get through a softer year. But here's where the debate starts. On the right, you're paying roughly 37 times forward earnings against a 5-year average of 29. On the left, your starting dividend yield is dropped to about a third of a percent. The 5-year average is sitting at 0.5%. And if we get to the blue tunnel from Simply Safe Dividends highlighting intrinsic fair price while it's sitting above the upper end, that indicates to us a potential overvaluation signal for which over the last 10 years and five in fact, Apple is one of those companies that investors they pay a premium for. Very, very rarely do you actually get to see it in an undervalued level. And also worth highlighting that Wall Street, the only one with a buy rating being very weak at that. Well, on average, they actually see no upside for the company, downside of 3%. Their average target over the next year is $341 below today's price. Although there is a range, more bearish analyst 250, more bullish above $400 for which consensus has $940 of earnings for fiscal 2027. That's growth of just under 5%. Now, the following year is stronger. But we can see growth just above 12%. And that pickup is part of the bull case. And if we move to the growth table, bit of a cross check. Forward revenue expected 11%. Long-term earnings growth we can see 8.3%. In fact, in both cases, they're significantly below what the sector is expecting. EPS much higher at 21%. Even their own 5year average sits high at 11%. So whilst it is growing is a lot slower than both their past and in fact the sector. Now try this quick check with me. If we put 29 times historical multiple on this $940 estimate, it gets you to about $273. I want a clear reason to pay materially more than that. And this is where my cash flow model comes in. I start from 2026's record year, $136 billion. And then I apply a 10% growth rate moving forwards, 9% discount rate with 3% terminal growth. But also look how lumpy their free cash flow has been. Cash flow in fact it fell 11% in 2023 and as well 2025 down 9% before the jump that we've seen in 2026. Now I am going to give Apple credit for the rebound. I'm going to carry that pace forward. Now I would say bear in mind that is quite a big assumption here. At 8% growth will we get around $233. at 10% growth 272 and at 12% we get 317 even the highest case today of the three 12% it's fallen short by 9% in terms of the price today at $350 that indicates today Apple is trading at a premium of 29% and if we work backwards from the market price today of $350 while the stock it needs roughly 13.3% annual cash flow growth for a decade that's the hurdle I'm weighing against a starting point that's already a record year. My call for Apple near $350 is to take some money off the table. If the earnings trajectory gets stronger, I can revisit what I pay at this price. For me, I'd reduce the Apple position. So, Apple for me is going in the trim column with roughly 270 to 280 as the range I'd revisit for this. The next stock though is got a much bigger one-day bounce and the model gives me a different answer. And before we jump into that stock, just to let you know, every single week I release one weekly article covering severely undervalued stocks as well as what's going on in the market. You can click on the pin comments, sign up, and read all of these straight away. The next stock we're looking at is Texas Instruments. That was up around 7% yesterday, trading just below $300. It's also up significantly. We're talking 70% in 2026. If you own it, I get why you think about taking profits over the last 5 years. This one's up not massively, only 55% trading near 52-E highs of $334 where yes, we do get a double buy rating, but both a week from C, Alfa, and Wall Street. And here's why I want to look at the numbers first. Sales growth on the right, we can see, has gone from two negative years to 20% over the latest 12 months. The earnings chart pretty much showing us the same turn. And the cash flow rebound, that's even bigger. We've got the chart going from under $3 per share in 2025 to more than eight over the last 12 months. How much of that improvement can I honestly carry forward? And we've also got operating margins, they've improved on the left and cash margins, they've recovered on the right. The earnings release, it shows us that operating cash flow is up while capex is down. Both have helped the cash coming through the business where return on invested capsule that's recovered to 21%. It supports the recovery story that it's still below the readings in the 30s from the last strong part of the cycle. I'd give that history some weight and good to see very importantly too the balance sheet is improved trailing net debt is around half of EBIT Dar. It gives the company room to get through the cycle while I see whether earnings can keep on recovering. And honestly for Texas Instruments, this is the part where it gets interesting. The yield is sitting around 2% below historical 2.8. But on the other side, we've got the forward multiple that's sitting around 26, slightly below the 5-year average of 28. So I can see both sides of it. Now, Wall Street, even with their weak buy rating, whilst with Apple, we saw in fact that they gave that one a slight loss over the next 12 months. For TXN, they actually see upside of 14%, average price target 337. Now the consensus EPS estimates it does help us out with Texas Instruments. We can see at today's price you're paying around 33 times the 2026 estimate. Move out to 2027 is close to the 26 times. That's on 1156 projections. We've also got forward growth numbers. They're looking strong both across sales and operating profit. Revenue expected 19% moving forwards. EBIT DAR 29% EBIT 32. Earnings per share 31%. Long-term earnings per share 28.3. What I'm trying to work out is what the business can keep compounding once the first few years of recovery are behind it. Now, analysts are projecting in 2026 free cash flow to ramp right up to $7.7 billion. From that, I'm then using a 15% growth rate. It gives us a fair value at $38. A little bit of upside, 4%, a little bit of margin of safety, too, at 4.2. In terms of a buy, personally, whether it's TXM or any other companies, I definitely want a wider gap, especially when you consider it's had a fairly strong run. Now, change the assumption and the answer, it does move fast. At 10%, the model gives us a value of $218. At 20%, $432. These are both using the same cash flow projected by analysts in 2026. Now, we can see consensus. They are in fact expecting strong earnings growth over the next few years. It gives me a reason to take the recovery seriously. I still need that earnings growth to translate into cash for shareholders. And if we work backwards from 295 the price today, well, we can see it needs around 14.4% growth after fiscal 2026, I can see that happening only if the recovery carries on. That's the hurdle for Texas Instruments. So around today's price, $295. I would say this is probably my first hold using the stronger recovery case. The price is close enough to the base case. What I would do here is revisit the position if recurring cash flow starts pointing towards the slower case. Now, if we just go back to the S&P over the last month, we've got quite a lot of green in financials and healthcare, while some of the biggest tech stocks are red. We're going to go back to the initial conversation that we heard at the beginning of the episode. Kevin Gordon has a piece here. What he said, in fact, makes a good point about how much those big names, they can distort the overall picture. We're going to take a listen. >> Definitely had a big wash out last week, but I think that's setting us up for the bottom. So, I think markets are a lot safer than people think. >> What do you think? So I think that we're still in sort of this knife falling you know territory where you don't want to necessarily you don't want to necessarily I think extrapolate any particular day in terms of what the cap weighted market is doing and I say that because I think the better signal that you got uh throughout last week whether it was post election the day after the election whether it was the massive draw down day is that throughout all of that um you still had equal weighted S&P outperforming the cap weighted S&P you still had you know almost 60% of members above their 200 day moving average by the end of last week most of the stress was concentrated on what those leverage and and highly leveraged bets were within the tech space. >> Some of the shares people bought for defense, they already carry a premium. Healthcare is above its own historical multiple here. That's where I want to go next because this stock, it shows that very clearly. And that's Johnson and Johnson trading around $280. Now we can see that's pretty much sitting around not only 52- week but also all-time high for the company where it's up 36% in 2026. You've already got a very strong rerating for the company over the last 5 years. They're up 74%. We do get one buy rating. It is from Wall Street. Respectful 4.1 out of five. And there's a reason that people have been buying it. Newer drugs, they help drive results. and management raised their adjusted earnings outlook to $115 through to $11.15 for the full year. And if we look at their margins while trading free cash flow that's sitting at 21% and it's been around that level for quite a number of years that kind of stability it goes a long way to explaining the premium of J&J. Balance sheet also makes a very similar point. Trailing net debt is around8 EIT dollar. That's part of what you're getting with Johnson Johnson. But how much extra as an investor are you prepared to pay for that? And this is the chart I'd spend time on. You're paying 25 times forward earnings against 16 over the last 5 years. The yield has also fallen dramatically 1.9% 5-year average sitting much higher at 2.8. So probably no surprises when we look at the blue tunnel and we can see pretty much all the way from the beginning of 2026 J&J has entered quite a severe premium stage. Look at the last 5 years, 10 years. This actually was never a company that used to trade at premium. We're now seeing that happen in 2026. And Wall Street, even with their respectful buy, they actually see downside over the next year. Pretty much saying they believe Johnson Johnson today is worth fair price with no upside at least over the next 12 months. Their target comes just shy of $280. Now the consensus EPS table is got 4 and a.5% earnings growth in 2027 and nearly 20% growth in 2028. That is quite a big step up for J&J. What I want to know as an investor is how much room there is if it actually starts to take longer with a longerterm number here over the next 3 to 5 years. That's it around 7% earnings growth. I'm taking that as a broad check. Estimates for individual years they can jump around especially when they're coming off a weaker comparison. Now, my DCF model per analyst expectations for 2026, it starts off at $21 billion of free cash flow. From there, I give the business 8% annual growth. That gets it to around $42 billion of free cash flow in the final forecasted year. And even on the stronger 2028 estimate, you're paying around 20 times earnings at the current price. You've got to wait for those earnings to show up. I'd want more if that estimate comes down. And then if we turn it around around $280, I need roughly 30 and a half% annual cash flow growth after the starting year. That's quite a big difference from the 8% that I've used in my base case today. Now management, they are in fact giving us adjusted earnings guidance. It helps me understand the drug business for the cash shareholders can receive. I also have to think about the future payments tied to the talc matters. Now looking at the other models here as well, the dividend discount, it gives me $188. the cash flow model that we ran through $192 where the multiples comes to $220. Now, if we take the average $200, in fact, that equates to quite a significant premium, we're talking around 41%, even the highest valuation here, which is the multiples, $ 220, that sits significantly below the value we've got today. Where the dividend now, it's starting at just under 2%. From there, you're relying on earnings growth and the multiple that people will pay. If the multiple falls back towards the historical range, it can eat into the growth. Johnson and Johnson. It has the largest premium of my four trims using these models, which makes it the first one I'd review in the portfolio. So for me today, J&J is a trim at this level. Around $200 is where I'd revisit the thesis based on the work. At $282, I take advantage of what investors are willing to pay for the shares. So that's two trim so far. The next stock has also had a big run, and the later results make the decision harder. What convinced me was seeing how the three valuation methods ended up lining up. Now Coca-Cola is trading around $96 is up 37% year to date. That is quite a big run for a stock people buy for a steady dividend. Would you start that position today? I mean over the last 5 years is up around 70% trading pretty much around all-time highs of $97 with just one buy rating although very respectful from Wall Street 4.3. Seek Alpha coming in with a hold. I mean, look at what a new buyer gets. On the left is a 2.2% yield versus around 2.9 over the five years. On the right is nearly 28 times forward earnings versus 23 on a historical basis. Where the blue tunnel is telling us the company looks potentially overvalued. Look at the last 10 years. Again, Coca-Cola is not a company that typically trades at a premium. You'd have to go to 2020 just the beginning or 2017 before that to see it in an identical situation. Now give Koke Stew earnings and revenue they've picked up in the latest quarter global unit case volume that rose 5%. It tells you something about where the growth is coming from and the operating margin has been around 30% for many many years is one reason Coke commands a premium. The question for me is whether the premium you see today still leaves enough of a return where net debt that's also improved as well. The charts got it around 1.5 times trading EBIT DA taken with those margins. This is definitely a business I'm happy to watch. My decision for co it comes down to the price and Wall Street even as we said earlier with a fairly respectful buy. They only see 2% upside their average target is $98 pretty much at their all-time high. Now the range is wide. In fact, more so on the bottom end with the more bearish analysts see around $80. And as an investor, you're paying almost 29 times the 26 estimate and around 27 times the 2027 consensus. They've got just under 6% earnings growth next year. I definitely want a better price for that sting growth. Now, the cash flow chart, it does need a bit of care. There's a big jump from the last two years into the trading figure. In 2024, you have the tax deposit. And in 2025, you have the fair life payment. Adjust those years for their respective payments. And cash flow goes from around 10.8 billion to 11.4 billion. That's around 6% growth. That's the comparison I'd use to judge what is exactly repeatable. Now, a big percentage jump in the growth table. It can in fact send you down the wrong path here. Check what's in the base period. For the valuation, I care about the cash flow CO can produce year after year. and management. They've actually guided to at least $13 billion in free cash flow this year. That's exactly what I've used for 2026. And then we're using a growth rate of 10% moving forwards. It takes the cash flow past 30 billion in 2035. Even with that growth, the DCF, it only comes to around $75. My other methods, as we can see here, they come to 75. We just went through DDM 74, multiples 87. You can pick the most generous of the three and you're still below the market price today of $96. In fact, to make $96 work, you can see here you need around 13.5% annual cash flow growth after this year. If you believe CO can sustain that, I understand paying up. My assumptions though they are lower. And there's also a quick sense check. Use the 5-year multiple of around 23 times and a half on next year's $353. If it was a stock in the low80s, I'm getting broadly the same message here. The blended number is $79. We can see that's a 22% premium today. Now, around the high70s, I'd be more interested in doing the work. Again, for me, I trim Coke around $96. If you bought it for income, ask yourself what you're earning on the money that's tied up in the position today. At this price, it's a little over 2%. So, that's three positions I'd reduce. The next company pays close to 6%, so the income changes the decision. It also has my favorite child in the episode, the stock return in shipments. They've gone in opposite directions. Look at this. From the third quarter of 2021 to the third quarter of 2026, we can see here 152% total shareholder return. That's including dividends. Trading domestic cigarette shipments, they fell around 37%. Now ultra it is in fact up 31% year to date trading at $7576 where in fact the dividend yield is sits just below 6% if you own it for income is a different starting point than from what we just saw with coke also one first time today where we get a hold right across the board seeking out for wall street and quant where over the last 5 years it is up around 70%. is also the second one where Wall Street actually see downside over the next year. We're talking 3% their average target $73. And one thing that's quite important for a company like Ultra that pays quite a high dividend, we said it's around 6%. Net dead to EBIT Dart, we want it below three and in particular for tobacco companies. Well, it looking very strong from the highs of 2018 at 2 and a half. It's come all the way down to 1.66. So very promising, especially as expected to come down moving forwards. Here's what I'm watching. Discount cigarette shipments. They were up around 40% year-over-year in the latest quarter, while marvel shipments fell more than 6%. I want to see how much of that mix shift persists. And we've got a chart. It runs to 2020, so just bear that in mind. But it measures cigarette smoke per American adult. The trend has been down for decades. So part of value in Ultra is working out how much you can rely on pricing from here. And we have long-term earnings growth that's sitting around 4.3%. Forward revenue, that's barely even hitting 1%. Now, Ultra, they still raised adjusted earnings guidance. It gives you a decent counterargument to the volume story. Now, the comparison I care about the most is the yield against what Ultra normally offers. You're getting 5.9% against a 5year average of 7.8. The multiple that's gone up to sitting around the highs, 12.9 against a 5year average of 9.8 a at $7576 while the $444 here annualized dividend that does real work for the return. Can the cash flow support that payout as volumes keep falling? That's what I'd want to test. Now, I start from Ultra's 2025 free cash flow figure of $9.1 billion. And then I use around 3% growth, which is in line with their 5year keer, although much lower than their 10year of 11%. And that in turn gives me a DCF value of $81. This chart is why I model the cash flow alongside the shipment figures. Investors got paid while volumes fell. The question is how much of that can happen again from a price of $75. And at today's price of 75, the reverse model it needs around 2% annual cash flow growth is a fairly low hurdle. If pricing can keep carrying cash flow, I can see a case for holding. Now, here's why the summary is actually giving us an overvaluation signal. The Graeme estimate we're getting to $47. It does pull all the methods down to around 70 as we can see on average. The cash flow and dividend model they do give around $80 as we can see on an average basis. Now the multiple is above Altria's own 5year average. It's a very good reason to be selective. Even with the yield, if the price gave me the old yield again, I'd have a lot more room to absorb weaker growth. And as a sensitivity check, if we in fact just use these three models here, we get to a price around $77 close to the share price today. So a sell decision based on the four method average. It puts a lot of weight on this one low estimate. At a price around $75, $76, I'd probably hold. I'm getting paid to wait and most of the values are close to the price. I'd keep checking what happens to cash flow as the cigarette mix changes. So Ultra, my second hold. We've got one trim left. The last company is growing online sales and advertising quickly. Can those businesses make enough of a difference to justify what the whole stock costs? And that stock is Walmart, trading at $126, up 30% year to date. Now, the most important number on this page is actually the earnings multiple you're starting with. We'll touch that in a sec, but just look in terms of where it sits near 52- week all-time high, one buy rating. In fact, that's pretty much on the border of a strong buy at 4 1/2. Where when we look at valuation, they're trading at 42 times Ford earnings against a 5year average of just under 26 yield that's below 1%. What does Walmart have to become to justify that price? Now, the latest quarter gives the balls plenty to work with. Global e-commerce sales, they rose 23% and advertising that rose 38. You can see why people want to value Walmart as more than just a chain of stores. Now look at the black bar. US comparable sales rose 2.6% excluding fuel down from 4.6 a year earlier. That's the other side of the story when you're paying this kind of a multiple. Now revenue rose around 6% and we can see operating profit that improved at 1 percentage point the quarter. It also benefited from tariff refunds. I'm giving Walmart credit for the progress while looking for evidence that the underlying margin can keep on improving. Net debt to EBIT DAR as well that's in fact just slightly over one 1.23. The balance sheet gives Walmart room to keep investing in stores and online. What I'm questioning is the price I'm paying for that growth. And Wall Street, funnily enough, even with a very close to being a strong buy, they only see 2% upside 1 to8 price target, but more bullish see it as high as 155. Now, Consensus has $289 of earnings for the fiscal year ending in January 27. That's around 9.3% growth. On those specific earnings, the share price is 43 and a half times. And if we look further down this table, well, we can see operating cash flow improving. That was up 12% year-over-year. However, when we contrast that to free cash flow, that was down around 15%. How much of the cash coming in does Walmart have to put straight back into the business? Now, my DCF starts around $15 billion of free cash flow, what Walmart did last fiscal year. The latest versile figure was around 5.5 billion as capex rose. That I'm watching very closely. And this chart is trailing earnings as of November 6. It puts Walmart at 46 times against its own 10-year median that sits around 30. It gives you the same broad picture as what we discussed earlier. And I've started with 15% annual cash flow growth for 10 years. That's already taking the online and advertising opportunity seriously. Even with that assumption at the discount rate of 9%, I get a value of around $73. And if we go back to the earnings table for a second, some of these years show doubledigit growth to justify the share price in my model. I need to see more of that earnings growth turning into cash. Now look at the high case. At 20% cash flow growth, the model comes to $109. to get to 125 which is today's value. Well, it needs almost 22% a year for 10 years. Now the dividend model we can see it comes to $137 that's above today's value. Multiples that comes around 93 average those with the DCF we get to $101 indicating a 24% premium today. I can see why warm up would get a higher multiple than it used to. How much higher is the question. With a yield below 1%, you're leaning on growth and the multiple staying high. Now, Walmart reports on November 19th around 125, I'd probably take some money off the table. What could change my mind is clearer evidence that today's spending is turning into durable cash flow. I'd put Walmart in the trim column. Around $100 is where I'd revisit on these assumptions. The dividend model, it gives you a reason for a different view. The cash flow hurdle, it settles it for me. At the next report, check this figure alongside cash flow. If both are improving, that's a better argument for paying a premium. I'll check those numbers against the valuation when they come out. Now, here's my order based on the gaps in the model. Johnson and Johnson is the first trim I'd look at. The price at $280 against a blended estimate of around 200. That's the widest gap. Apple, that's next for me. You got a record cash flow year around $350. You still need growth to stay high. I'd reduce it here and revisit closer to $270 $280. Walmart is my third trim by the size of the gap. I'll go back to the model after earnings, but at the current price, the cash flow the stock needs is a big big ask. Coke, well, that is my fourth. At $96, all three of my methods come in below the market price. I take some money off and reconsider around the high70s, provided the volume and cash flow story still looks healthy. Texas Instruments is one of my two holds. The base case is close to the share price and it depends on the cash flow recovery. If the next numbers point to a slower path, it's something I definitely revisit. Ultra is my other hold. The cash flow and dividend models give me enough reason to keep collecting the income here. But let me know which trim do you disagree with the most. If you enjoyed the episode, smash the like button, hit the subscribe and bell so you're aware of future episodes. And don't forget to click on the pin comment where you can sign up read these straight away. More importantly, have a great day. I'll see you all on the next one.

Comments 0

No comments yet. Be the first to share your thoughts!